We advised MicroTech Medical on its IPO and HKEX listing

Davis Polk advised MicroTech Medical (Hangzhou) Co., Ltd. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Rule 144A and Regulation S. The net proceeds from the offering amounted to approximately HK$1.82 billion (US$233 million) prior to the exercise of the over-allotment option.         

Founded in 2011, MicroTech Medical has been focused on diabetes management, providing both diabetes treatment and diabetes monitoring medical devices to improve diabetes management in China and globally.

The Davis Polk corporate team included partners Yang Chu and Xuelin (Steve) Wang, counsel Lillian Lian, associates Sarah Shi and Jeffrey Lee and registered foreign lawyer Jerry Wu. Counsel Alon Gurfinkel and associate Omer Harel provided tax advice. Associate Sijia Cai provided 1940 Act advice. Members of the Davis Polk team are based in the Hong Kong, London and New York offices.

Copy link to share post